UMM Logo

Universitas Muhammadiyah Malang


Free Download Journals Directory


International Journal Of Bilogical Sciences

.: Home > International Journal Of Bilogical Sciences > 2012 > Volume 8 Number 3 > Liwen Zhang1✉, Timothy McCabe2, Jon H. Condra2, Yan G. Ni1, Laurence B. Peterson1, Weirong Wang3, Alison M. Strack1, Fubao Wang2, Shilpa Pandit1, Holly Hammond2, Dana Wood2, Dale Lewis1, Ray Rosa1, Vivienne Mendoza1, Anne Marie Cumiskey1, Douglas G. Johns1, Barbara C. Hansen10, Xun Shen1, Neil Geoghagen1, Kristian Jensen1, Lei Zhu5, Karol Wietecha5, Douglas Wisniewski4, Lingyi Huang, Jing Zhang Zhao, Robin Ernst, Richard Hampton, Peter Haytko, Frances Ansbro7, Shannon Chilewski7, Jayne Chin1, Lyndon J. Mitnaul1, Andrea Pellacani6, Carl P. Sparrow1, Zhiqiang An2,8, William Strohl2,9, Brian Hubbard1, Andrew S. Plump1, Daniel Blom1, Ayesha Sitlani1✉

An Anti-PCSK9 Antibody Reduces LDL-Cholesterol On Top Of A Statin And Suppresses Hepatocyte SREBP-Regulated Genes

Liwen Zhang1✉, Timothy McCabe2, Jon H. Condra2, Yan G. Ni1, Laurence B. Peterson1, Weirong Wang3, Alison M. Strack1, Fubao Wang2, Shilpa Pandit1, Holly Hammond2, Dana Wood2, Dale Lewis1, Ray Rosa1, Vivienne Mendoza1, Anne Marie Cumiskey1, Douglas G. Johns1, Barbara C. Hansen10, Xun Shen1, Neil Geoghagen1, Kristian Jensen1, Lei Zhu5, Karol Wietecha5, Douglas Wisniewski4, Lingyi Huang, Jing Zhang Zhao, Robin Ernst, Richard Hampton, Peter Haytko, Frances Ansbro7, Shannon Chilewski7, Jayne Chin1, Lyndon J. Mitnaul1, Andrea Pellacani6, Carl P. Sparrow1, Zhiqiang An2,8, William Strohl2,9, Brian Hubbard1, Andrew S. Plump1, Daniel Blom1, Ayesha Sitlani1✉
1. Department of Atherosclerosis, Merck Research Laboratories, Rahway, NJ 07065; 2. Department of Biologics Research, Merck Research Laboratories, West Point, PA 19486; 3. Department of Preclinical DMPK, Merck Research Laboratories, West Point, PA 19486; 4. Department of In Vitro Sciences, Merck Research Laboratories, Rahway, NJ 07065; 5. Department of GEM Target Validation, Merck Research Laboratories, Rahway, NJ 07065; 6. Department of MBV and Early Biologics, Upper Gwynedd, PA 19454; 7. Department of Bioprocess and Bioanalytical, Merck Research Laboratories, West Point, PA 19486; 8. Present address: University of Texas Health Science Center, Houston, TX; 9. Present address: Centocor R&D, Inc., Radnor, PA 19087; 10. Departments of Internal Medicine and Pediatric, University of South Florida, Tampa, FL 33612.
Abstract :

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a promising therapeutic target for treating coronary heart disease. We report a novel antibody 1B20 that binds to PCSK9 with sub-nanomolar affinity and antagonizes PCSK9 function in-vitro. In CETP/LDLR-hemi mice two successive doses of 1B20, administered 14 days apart at 3 or 10 mpk, induced dose dependent reductions in LDL-cholesterol (≥ 25% for 7-14 days) that correlated well with the extent of PCSK9 occupancy by the antibody. In addition, 1B20 induces increases in total plasma antibody-bound PCSK9 levels and decreases in liver mRNA levels of SREBP-regulated genes PCSK9 and LDLR, with a time course that parallels decreases in plasma LDL-cholesterol (LDL-C). Consistent with this observation in mice, in statin-responsive human primary hepatocytes, 1B20 lowers PCSK9 and LDLR mRNA levels and raises serum steady-state levels of antibody-bound PCSK9. In addition, mRNA levels of several SREBP regulated genes involved in cholesterol and fatty-acid synthesis including ACSS2, FDPS, IDI1, MVD, HMGCR, and CYP51A1 were decreased significantly with antibody treatment of primary human hepatocytes. In rhesus monkeys, subcutaneous (SC) dosing of 1B20 dose-dependently induces robust LDL-C lowering (maximal ~70%), which is correlated with increases in target engagement and total antibody-bound PCSK9 levels. Importantly, a combination of 1B20 and Simvastatin in dyslipidemic rhesus monkeys reduced LDL-C more than either agent alone, consistent with a mechanism of action that predicts additive effects of anti-PCSK9 agents with statins. Our results suggest that antibodies targeting PCSK9 could provide patients powerful LDL lowering efficacy on top of statins, and lower cardiovascular risk.

Keywords :
PCSK9, low density lipoprotein cholesterol (LDL-C), hypercholesterolemia, LDL receptor, sterol regulatory element binding protein (SREBP), primary hepatocytes

Date Deposited : 09 Apr 2015 10:44

Last Modified : 09 Apr 2015 10:44

Official URL: http://www.ijbs.com/ms/archive

Volume 8, Number 3, - 2012 , ISSN 1545-1003

Download:
Full Text Original
Abstract : pdf doc
Home | Peta Situs | Admissions | Student Research | E-Journal
Universitas Muhammadiyah Malang © 2011
Developed by Infokom UMM
Last Update : 13 December 2016 20:46Kumpulan file jurnal